Product Description
Deoxycholic acid injection is used to improve the appearance and profile of moderate to severe submental fat ('double chin'; fatty tissue located under the chin). Deoxycholic acid injection is in a class of medications called cytolytic medications. It works by breaking down cells in fatty tissue. (Sourced from: https://medlineplus.gov/druginfo/meds/a615026.html)
Mechanisms of Action: Cell Wall Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous,Subcutaneous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Australia | Austria | Belgium | Brazil | Bulgaria | Canada | Chile | Croatia | Czech | Denmark | Estonia | Finland | Germany | Greece | Hong Kong | Hungary | Iceland | Indonesia | Ireland | Italy | Korea | Latvia | Lithuania | Malta | Netherlands | New Zealand | Norway | Poland | Portugal | Romania | Singapore | Slovakia | Slovenia | Spain | Sweden | Switzerland | Taiwan | United Kingdom | United States
Approved Indications: None
Known Adverse Events: None
Company: Kythera
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, China
Active Clinical Trial Count: 3
Highest Development Phases
Phase 1: Oncology Solid Tumor Unspecified|Other
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ACTRN12618001112257 | P1 |
Recruiting |
Oncology Solid Tumor Unspecified |
2021-06-30 |
|
| ACTRN12618001070224 | P1 |
Recruiting |
Oncology Solid Tumor Unspecified |
2020-04-30 |
|
| CTR20200686 | P1 |
Recruiting |
Other |
None |